Literature DB >> 28332145

[The role of pelvic irradiation in node-negative prostate adenocarcinoma remains unclear : Long-term results from the GETUG-01 study].

Matthias G Hautmann1, Oliver Kölbl2.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28332145     DOI： 10.1007/s00066-017-1125-x

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  4 in total

1.  Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG #77-06, a phase III study for T1BN0M0 (A2) and T2N0M0 (B) prostate carcinoma.

Authors:  S O Asbell; K L Martz; K H Shin; W T Sause; R L Doggett; C A Perez; M V Pilepich
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-03-01       Impact factor: 7.038

2.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

Authors:  A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein
Journal:  JAMA       Date:  1998-09-16       Impact factor: 56.272

3.  An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions.

Authors:  Colleen A Lawton; Michelle DeSilvio; Mack Roach; Valery Uhl; Robert Kirsch; Michael Seider; Marvin Rotman; Christopher Jones; Sucha Asbell; Richard Valicenti; Stephen Hahn; Charles R Thomas
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-05-24       Impact factor: 7.038

4.  Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01.

Authors:  Pascal Pommier; Sylvie Chabaud; Jean Leon Lagrange; Pierre Richaud; François Lesaunier; Elisabeth Le Prise; Jean Philippe Wagner; Meng Huor Hay; Veronique Beckendorf; Jean Philippe Suchaud; Pierre Marie Pabot du Chatelard; Valerie Bernier; Nicolas Voirin; David Perol; Christian Carrie
Journal:  J Clin Oncol       Date:  2007-12-01       Impact factor: 44.544
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.